Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USP certification program

This article was originally published in The Tan Sheet

Executive Summary

Srini Srinivasan, PhD, named VP-Dietary Supplement Verification Program, group says May 2. Srinivasan has served as acting VP since March 5, when former DSVP head Forouz Ertl stepped down after leading program from pilot phase through launch (1"The Tan Sheet" Nov. 19, 2001, p. 16). Certification program is now available on the Web at 2www.usp-dsvp.org...

You may also be interested in...



USP management

David Roll, PhD, appointed director of dietary supplements, effective Aug. 19, group announces Sept. 5. Roll replaces Srini Srinivasan, PhD, who has served as interim director since his promotion in May to VP-Dietary Supplement Verification Program (1"The Tan Sheet" May 6, 2002, In Brief). A 12-year member of USP's Council of Experts and recently chair of USP's Expert Committee on Dietary Supplements, Non-Botanicals, Roll has spent the past year as a congressional fellow for Sen. Byron Dorgan (D-N.D.) following a 30-year career as professor of medicinal chemistry at the University of Utah...

NNFA, NSF Unite Supplement Testing Efforts; USP Program Clears Board

The dietary supplement certification alliance formed by NSF International and NNFA will yield cost efficiencies for firms participating in both programs and could make testing more affordable to smaller manufacturers, the groups said

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel